Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline.

MLA

Tanneau, Lénaïg, et al. “Population Pharmacokinetics of Delamanid and Its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline.” Clinical Pharmacokinetics, vol. 61, no. 8, Aug. 2022, pp. 1177–85. EBSCOhost, https://doi.org/10.1007/s40262-022-01133-2.

APA

Tanneau, L., Karlsson, M. O., Diacon, A. H., Shenje, J., De Los Rios, J., Wiesner, L., Upton, C. M., Dooley, K. E., Maartens, G., & Svensson, E. M. (2022). Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline. Clinical Pharmacokinetics, 61(8), 1177–1185. https://doi.org/10.1007/s40262-022-01133-2

Chicago

Tanneau, Lénaïg, Mats O Karlsson, Andreas H Diacon, Justin Shenje, Jorge De Los Rios, Lubbe Wiesner, Caryn M Upton, Kelly E Dooley, Gary Maartens, and Elin M Svensson. 2022. “Population Pharmacokinetics of Delamanid and Its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline.” Clinical Pharmacokinetics 61 (8): 1177–85. doi:10.1007/s40262-022-01133-2.